Back to search

Peptide record

TPDB13291

Brevinin-1HY Antibacterial Anticancer Antifungal Hemolysis Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB13291
Brevinin-1HY
Antibacterial Anticancer Antifungal Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia CancerPPD 2.0 CAFPdb dbAMP PD_Hemolysis
standard
No
A 21-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, CancerPPD 2.0, and other sources, with an available 3D structural model.
Sequence
FALGAVTKVLYKLFCLITRKC
Physicochemical Analysis
C113H187N27O25S2
NDEQHMPSW
L
2388.01
10.08
4
0
12
+4
-2.36
1.095
130.00
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
1615
67.63
5
Residue Composition
number
2
A
1
R
0
N
0
D
2
C
0
E
0
Q
1
G
0
H
1
I
4
L
3
K
0
M
2
F
0
P
0
S
2
T
0
W
1
Y
2
V
Amino Acid Distribution
A: 2 R: 1 N: 0 D: 0 C: 2 E: 0 Q: 0 G: 1 H: 0 I: 1 L: 4 K: 3 M: 0 F: 2 P: 0 S: 0 T: 2 W: 0 Y: 1 V: 2
Chemical Descriptors
21
C113H187N27O25S2
2388.01
10.08
+4
-2.36
1.095
Free
L
Linear
Free
Antimicrobial
Analogue of Brevinin-1H
Evidence Records 8 records
Evidence 1 Activity

Activity

IC50
IC50 = 5.425 µM
Anticancer
5.425 µM

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 2.243 µM
Anticancer
2.243 µM

Target

Breast Cancer
MDA-MB-435S
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 3 Activity

Activity

IC50
IC50 = 2.811 µM
Anticancer
2.811 µM

Target

Lung Cancer
H-157
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 4 Activity

Activity

IC50
IC50 = 3.583 µM
Anticancer
3.583 µM

Target

Colon Cancer
HCT-116
Colon

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 5 Activity

Activity

28.48% Hemolysis
Toxicity
4 µM
Hemolytic Cytotoxic
28.48% Hemolysis | 4 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Characterisation of a novel peptide, Brevinin-1H, from the skin secretion of Amolops hainanensis and rational design of several analogues. | Chem Biol Drug Des | 2020
Evidence 6 Activity

Activity

90% Hemolysis
Toxicity
16 µM
Hemolytic Cytotoxic
90% Hemolysis | 16 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Characterisation of a novel peptide, Brevinin-1H, from the skin secretion of Amolops hainanensis and rational design of several analogues. | Chem Biol Drug Des | 2020
Evidence 7 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: Horse blood cells: The haemolysis at the MIC of Brevinin-1HY (28.48%) was more than threefold at the MIC for the parent peptide

Target

erythrocytes

Source & Reference

NA
DRAMP
Chem Biol Drug Des. 2021 Feb 97(2):273-282.
Evidence 8 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis